DIFFERENTIAL-EFFECTS OF DOXAZOSIN ON CLINIC AND AMBULATORY PRESSURE ACCORDING TO AGE, GENDER, AND PRESENCE OF WHITE COAT HYPERTENSION - RESULTS OF THE HALT STUDY

被引:52
作者
PICKERING, TG
LEVENSTEIN, M
WALMSLEY, P
机构
[1] Hypertension Center, The New York Hospital-Cornell Medical Center and Pfizer-Roerig, Inc., New York, NY
关键词
WHITE COAT HYPERTENSION; DOXAZOSIN; BLOOD PRESSURE;
D O I
10.1093/ajh/7.9.848
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
In this study the effects of a single daily dose of doxazosin (an alpha-adrenergic blocker) given at night were evaluated in 112 patients with mild hypertension. Patients were studied first on no medication, and a second time after being treated for up to 16 weeks with doxazosin. Blood pressure (BP) was measured by noninvasive ambulatory monitoring at the beginning and end of the study. Before treatment, the white coat effect (clinic-ambulatory BP) was greater in women than in men (significant for systolic pressure but not diastolic), and greater in elderly (aged over 65 years) than in younger patients (significant for both systolic and diastolic pressure). Clinic and ambulatory BP were reduced to a similar extent in men and women by doxazosin, but in the elderly the fall in clinic BP was associated with a much smaller fall of ambulatory BP. In patients with white coat hypertension (elevated clinic but normal ambulatory BP) doxazosin lowered clinic but not ambulatory BP, while in those with sustained hypertension it lowered both.
引用
收藏
页码:848 / 852
页数:5
相关论文
共 16 条
  • [1] Pickering T.G., Ambulatory monitoring and blood pressure variability, (1991)
  • [2] Pool J.L., Taylor A.A., Nelson E.B., Review of the effects of doxazosin, a new selective alpha1-adrenergic inhibitor, on lipoproteins in patients with essential hypertension, Am J Med, 87, pp. 53S-56S, (1989)
  • [3] Rosenthal J.R., Clinical experience with doxazosin in general practice, Am Heart J, 116, pp. 1748-1757, (1988)
  • [4] Hay Duck K., Schmeider H.T., Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin, Am J Cardiol, 59, pp. 95G-98G, (1987)
  • [5] Levy D., Walmsley P., Levenstein M., Principal results of the Hypertension and Lipid Trial (HALT), Am J Hypertens, 698, (1993)
  • [6] Pickering T.G., Levenstein M., Walmsley P., Nighttime dosing of doxazosin has peak effect on morning ambulatory blood pressure. Results of the HALT study, Am J Hypertens, 7, pp. 844-847, (1994)
  • [7] Pickering T.G., James G.D., Boddie C., Et al., How common is white coat hypertension?, JAMA, 259, pp. 225-228, (1988)
  • [8] Gould B.A., Mann S., Davies A.B., Et al., Does placebo lower blood-pressure?, Lancet, 2, pp. 1377-1381, (1981)
  • [9] Dupont A.G., Van Der Niepen P., Six R.O., Placebo does not lower ambulatory blood pressure, Br J Clin Pharmacol, 24, pp. 106-109, (1987)
  • [10] Parati G., Pomidossi G., Casadei R., Et al., Evaluation of the antihypertensive effect of celiprolol by ambulatory blood pressure monitoring, Am J Cardiol, 61, pp. 27c-33c, (1988)